Navigation Links
MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor
Date:12/4/2008

GAITHERSBURG, Md., Dec. 4 /PRNewswire/ -- MedImmune today announced that it has initiated a Phase 2 clinical trial in patients with chronic asthma to determine the safety of subcutaneous dosing of a humanized monoclonal antibody (MAb) that targets the interleukin-5 receptor (IL-5R). Preclinical data suggest that inhibiting the IL-5R pathway may lead to a targeted approach for treating patients with asthma, supporting continued study of this antibody.

"Asthma can be a very debilitating disease, and despite current therapies, patients are in need of novel treatment options," said Nestor Molfino, M.D., vice president, clinical development, pulmonary disease. "Some asthmatics may show an increased circulation of eosinophils in blood -- a certain type of white blood cell believed to play a critical role in the severity and disease pathway of asthma; therefore administration of this antibody may increase asthma control."

MEDI-563, which was generated using BioWa's POTELLIGENT(TM) Technology platform, has previously been investigated in a Phase 1 open-label dose-escalating study to evaluate the safety and tolerability of a single intravenous infusion in adults with mild-to-moderate asthma. Data from the completed Phase 1 study demonstrated that the antibody was well-tolerated with biologic activity producing substantial and prolonged depletion of blood eosinophils, thus supporting its continued development. Published literature suggests that reduction of eosinophils in sputum was associated with better asthma control and increases in sputum eosinophilia were associated with exacerbations of asthma. The antibody is also currently being evaluated in a double-blind, placebo-controlled Phase 1 study to evaluate the safety and tolerability and effects of the antibody on airway eosinophils in adults with asthma.

About Interleukin-5 Receptor (IL-5R)

Interleukin-5 is a cytokine secreted predominantly by T-lymphocytes, mast cells, and eosinophils involved in regulating the differentiation, proliferation, and activation of eosinophils via the IL-5 receptor, known as IL-5R. The IL-5R consists of an alpha chain and a beta chain. Expression of the IL-5R alpha chain is restricted largely to eosinophils, basophils, and some mast cells in humans. The alpha-chain exclusively binds IL-5 and the intracellular portion of IL-5Ralpha is involved in cellular activation. Thus, the IL-5R alpha.chain may be a good target for a therapeutic antibody in the management of asthma. Eosinophils, and perhaps basophils and some mast cells, can be preferentially targeted for antibody-dependent cell cytotoxicity through IL-5R alpha chain depleting cells thought to be key in disease pathogenesis and severity. In addition, blocking of IL-5R alpha could provide benefit by neutralizing effects of IL-5.

MedImmune's Clinical Development in Asthma

MedImmune has multiple approaches in development targeting asthma. Currently, in human testing, the company has antibodies targeting IL-9 and IL-13, in addition to the anti-IL-5R that is the subject of this press release.

About Asthma

Asthma is a chronic disease of the airways that may cause wheezing, breathlessness, chest tightness and coughing. According to the U.S. Centers for Disease Control and Prevention, more than 30 million Americans reported having a history of asthma in 2003, including nine million children. About 20 million said they currently had asthma. In 2000, the CDC reported that there were more than 10 million asthma-related outpatient visits to private physician offices and hospital clinics. The National Institutes of Health have estimated asthma-related healthcare costs in the U.S. at $14 billion annually.

About MedImmune

MedImmune is a leading, innovation-focused biotechnology company whose mission it is to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on infection, oncology, respiratory disease and inflammation, cardiovascular/ gastrointestinal disease and neuroscience. Headquartered in Gaithersburg, Maryland, MedImmune has approximately 3,000 employees worldwide and is the wholly owned biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN). For more information, visit MedImmune's website at http://www.medimmune.com.


'/>"/>
SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MedImmune Announces Zook as President
2. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
3. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
4. MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.
5. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
6. Pinnacle Biologics Announces Stock Purchase Agreement With MedImmune
7. MedImmunes Brian Rosen Honored by Montgomery County Chamber at 49th Annual Awards Dinner
8. Depth of MedImmunes Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society
9. MedImmune Fortifies Strategic Scientific Portfolio Management and International Leadership With New Executive Appointments
10. MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research
11. Seneca Valley High School Student Receives Science Award From MedImmune
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
Breaking Biology Technology:
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
Breaking Biology News(10 mins):